Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial
Open Access
- 7 August 2025
- journal article
- Published by Elsevier in Journal of Infection
- Vol. 91 (3) , 106576
Abstract
No abstract availableKeywords
Funding Information
- Manchester Biomedical Research Centre
- Modern Humanities Research Association
- National Institute for Health and Care Research (NIHR203292)
- Wellcome Trust (210755/Z/18/Z)
- Government of the United Kingdom
- Public Health England
- University Hospital Southampton NHS Foundation Trust
This publication has 11 references indexed in Scilit:
- Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373Vaccine, 2023
- Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trialJournal of Infection, 2023
- Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trialsClinical and Experimental Immunology, 2023
- Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trialThe Lancet Infectious Diseases, 2022
- Effects of Previous Infection and Vaccination on Symptomatic Omicron InfectionsNew England Journal of Medicine, 2022
- Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialThe Lancet Infectious Diseases, 2022
- Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.Journal of Infection, 2022
- Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in EnglandNature Medicine, 2022
- Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialThe Lancet, 2021
- Safety and Efficacy of NVX-CoV2373 Covid-19 VaccineNew England Journal of Medicine, 2021